Ashland explores potential sale amid suitor interest
The review follows months of pressure from activist investors who argue the company is undervalued and could unlock greater shareholder value through a change of control.
USA – Speciality cosmetic ingredient manufacturer Ashland Global Holdings Inc. is actively considering a potential sale after receiving takeover interest from both strategic buyers and private equity firms, a move that sent its shares up about 6% on the news.
The company, valued at USD 3.5 billion, has enlisted Citigroup and Lazard to advise on the process and is engaging with a range of suitors, though discussions remain ongoing and a transaction is not guaranteed.
Multiple large private equity groups have reportedly made contact, including Apollo Global Management, Carlyle Group, and Advent International, the latter known for beauty and personal care investments such as Olaplex, Laura Mercier, and Salt & Stone.
Standard Industries, already one of Ashland’s biggest shareholders via its investment platform, has also expressed interest in a potential deal, adding a strategic-financial hybrid dimension to the bidding landscape.
The push for a sale intensified after activist investor Ancora Holdings disclosed a significant stake in Ashland in June 2026 and publicly urged the board to consider strategic alternatives, including a sale.
Ancora’s presentation suggested a competitive process could support a take-out valuation around 11.5x EBITDA, implying roughly USD 76 per share, a premium of about 33% over then-current levels, and a sum-of-the-parts case above USD 80 per share.
By late June, a second activist, Cruiser Capital Advisors, also called for a sale, with both investors signaling potential proxy action if progress was not evident by September’s director nomination cycle.
In late July, Ashland and Ancora reached a “cooperation agreement,” under which Ashland expanded its board by appointing two new directors and formed a capital allocation advisory committee to guide strategic planning and capital returns.
Financial Backdrop: Q3 Performance and Cash Flow
The sale talks come against a backdrop of solid third-quarter results. Ashland reported Q3 sales of USD 497 million, up 7% year-over-year, with volume gains across all four business units.
The Personal Care segment was a standout, posting USD 155 million in sales, a 5% increase, driven by demand in skin care, biofunctional actives, and microbial protection ingredients.
Adjusted EBITDA slipped 4% to USD 109 million, weighed by operational challenges, inflation-related cost pressures, and higher incentive compensation costs.
Despite these headwinds, cash generation remained healthy, with USD 103 million in free cash flow and net leverage at 2.4x, in line with the company’s long-term target. Shortly after the results, the board declared a quarterly cash dividend, a move consistent with the newly formed capital allocation committee’s remit to oversee shareholder returns.
Sign up to receive our email newsletters with the latest news updates and insights from Africa and the World HERE.
